EIC Horizon 2020

---

Project Overview

Recent advances in genomics, molecular science, and big data are changing the way we define and target diseases, but drug discovery is still a time-consuming, expensive and risky process. Genome Biologics provides a unique combination of tools – GENIMAPS and GENISYST – to provide an  integrated platform, with a disruptive effect on the time, cost and risk  of drug discovery and pre-clinical trial development.

GENISYST uses a unique transgenic methodology to allow up to 50 genes to be  expressed in a pre-clinical model, directly in target tissue, without affecting the genome.The toolkit reduces the time to prepare  pre-clinical models, and the cost of drug discovery and pre-clinical  trials, by an order of magnitude. The impact of this is cheaper, more rapidly developed, drugs, with a greater target to market success rate. 

GENIMAPS combines big data, Ai and a unique multiomics approach to make rapid and precise matches between disease indicators and compound behaviours,  allow rapid identification of targets, genetic expression, and compound matches. As well as precision medicine, GENIMAPS also allows the rapid evaluation of an existing pipeline, allowing repositioning opportunities for FDA approved assets (or orphan drugs) – increasing the return on public and private investment.

Genome Biologics wins prestigious Horizon 2020 SME Instrument grant